---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033724"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:10:57.025252+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocugen reports 31% reduction in GA lesion growth at 12 months in Phase 2 OCU410 trial; plans Phase 3 in Q3 2026

## Summary
- 31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.
- No OCU410-related serious adverse events; no endophthalmitis, retinal detachment, or vasculitis reported.
- 27% slower rate of ellipsoid zone loss vs control, indicating photoreceptor preservation.
- Phase 3 pivotal trial with up to 300 subjects, adaptive design >95% power, expected to start Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-033724
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/0001104659-26-033724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/tm269664d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033724
- JSON: https://secwatch.observer/filing/0001104659-26-033724.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.